Awaiting product image

Article: Consistent superior benefit of cobimetinib/vemurafenib over vemurafenib monotherapy across mutation subtypes in BRAF-mutated advanced melanoma

€2.42

SKU: product-article-11327 Category:

Description

Consistent superior benefit of cobimetinib/vemurafenib over vemurafenib monotherapy across mutation subtypes in BRAF-mutated advanced melanoma

Reviews

There are no reviews yet.

Be the first to review “Article: Consistent superior benefit of cobimetinib/vemurafenib over vemurafenib monotherapy across mutation subtypes in BRAF-mutated advanced melanoma”

Your email address will not be published. Required fields are marked *

Related products